Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806745 | 0.93 | HSD17B10 (0.37) | HSD17B10ALOX12SMN1; SMN2CYP19A1MGAT2 | |
| SCHEMBL1802401 | 0.90 | HSD17B10 (0.42) | HSD17B10ALOX12SMN1; SMN2CYP19A1MGAT2 | |
| SCHEMBL1802875 | 0.81 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2CYP19A1KDM4ELMNA | |
| SCHEMBL4803750 | 0.80 | KDM4E (0.40) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL7684037 | 0.76 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL1802898 | 0.73 | SMN1; SMN2 (0.36) | HSD17B10SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL38953 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL20712625 | 0.71 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL24653312 | 0.70 | — | — | |
| SCHEMBL8106126 | 0.70 | TSHR (0.53) | HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369608-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2020-11-26 | — | — | US | disclosed |
| WO-2011052759-A1 | NOVEL NITROXYL RADICAL COMPOUND AND PROCESS FOR PRODUCTION THEREOF | 国立大学法人九州大学 (JP) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369608-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | MTAP, PRMT5, TET3 | HSD17B10 4785/4885ALOX12 4830/4885SMN1; SMN2 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.